ImmuPharma PLC
  • Announcements
  • About Us
    • About Us
    • Our Team
    • Board of Directors
  • Our Science
    • Our Science
    • ImmuPharma Biotech
    • Key Clinical Investigators
  • Pipeline
    • Pipeline
    • Autoimmunity & Inflammation
    • Anti-Infectives
  • Partnerships & Collaborations
  • Investors
    • Investors
    • AIM Rule 26 Information
    • Regulatory News
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Analyst Research
    • Interviews
    • Professional advisers
    • Email Alerts
  • Contact
Archives
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
December 24, 2024

Change of Auditor

Read More
December 04, 2024

Appointment of Company Secretary

Read More
October 11, 2024

Notification of Major Holding – Lanstead Capital

Read More
September 11, 2024

Extension of Warrants in Incanthera to 31 March 2025

Read More
August 06, 2024

TR1 – Major Holding – Lanstead

Read More
July 01, 2024

2024 Result of Annual General Meeting – all resolutions passed

Read More
June 05, 2024

Notice of AGM & Annual Report & Accounts

Read More
June 05, 2024

FINAL RESULTS for the twelve months ended 31 December 2023

Read More
June 03, 2024

Realisation of c£1.5 million on sale of shares in Incanthera plc

Read More
May 03, 2024

TR1 – Major Holding – Lanstead

Read More
April 24, 2024

IMMUPHARMA at BIO-EQUITY 2024 – 12-14 May 2024, San Sebastian

Read More
April 19, 2024

Grant of Share Options

Read More
  • 1
  • 2
  • Keep up-to-date with email alerts

  • @immupharma

Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2022 | All rights reserved